• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)
临床输血与检验

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (2): 235-238.DOI: 10.3969/j.issn.1671-2587.2022.02.020

• 临床检验 • 上一篇    下一篇

血清ProGRP阴性小细胞肺癌患者临床特点分析*

李明, 张倩, 吕磊, 戴春阳, 王保龙   

  1. 230031 中国科学技术大学附属第一医院（安徽省立医院）检验科
  • 收稿日期:2021-06-23 发布日期:2022-04-12
  • 通讯作者: 王保龙,男,主任技师,博士生导师,主要从事免疫学研究,（E-mail）wbl196555@163.com。
  • 作者简介:李明（1983-）,男,安徽人,副主任技师,博士,主要从事肿瘤免疫研究,（E-mail）liming19831002@163.com。
  • 基金资助:
    *本课题受安徽省自然科学基金项目（No.2008085MH288）资助

Clinical Characteristics of Small Cell Lung Cancer Patients with Negative ProGRP

LI Ming, ZHANG Qian, LV Lei, et al   

  1. Department of Laboratory Diagnostics, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031
  • Received:2021-06-23 Published:2022-04-12

RichHTML

2

PDF

942

摘要： 目的 研究血清胃泌素释放肽前体（ProGRP）阴性小细胞肺癌（SCLC）患者的临床特点。方法 回顾性分析2016年12月~2021年5月住院治疗的SCLC患者临床病例资料,其中ProGRP阴性患者25例,ProGRP阳性患者75例,比较两组患者临床病理特点和生存期差异,观察ProGRP阴性SCLC患者疗效监测过程中ProGRP水平动态变化。结果 ProGRP阴性的SCLC患者占比25%,ProGRP阴性和阳性SCLC患者在性别、年龄、吸烟史、临床分期和神经元特异性烯醇化酶（NSE）高水平率方面差异均无统计学意义。ProGRP阴性SCLC患者中,92%患者为广泛期（ED）,NSE阳性率为84%。ProGRP阴性SCLC患者无进展生存期（PFS）显著低于ProGRP阳性组。然而,血清ProGRP阴性SCLC患者,在肿瘤疗效监测的不同时期,甚至疾病出现进展时,血清ProGRP均处于较低水平。结论 血清ProGRP阴性的SCLC患者预后较差,可能是一类特殊类型的SCLC。

关键词: 小细胞肺癌, 胃泌素释放肽前体, 临床特点, 神经元特异性烯醇化酶

Abstract: Objective To explore the clinical characteristics of small cell lung cancer（SCLC）patients with negative pro-gastrin-releasing peptide precursor（ProGRP）. Methods The clinical data of hospitalized patients with SCLC between December 2016 and May 2021 were retrospectively analyzed. There were 25 negative ProGRP patients and 75 positive ProGRP patients. The clinicopathological characteristics and survival differences between the two groups were compared,and changes in ProGRP levels were observed during monitoring the effects in ProGRP-negative SCLC patients. Results ProGRP-negative SCLC patients accounted for 25%. ProGRP-negative SCLC patients and ProGRP-positive SCLC patients had no significant differences in gender, age, smoking history, clinical stage, and NSE positive rate. Of which, 92% were in extensive stage disease（ED）, and the positive reate of NSE was 84%. The progression-free survival（PFS）of ProGRP-negative SCLC patients was significantly lower than that of the ProGRP-positive patients. For ProGRP-negative SCLC patients,the serum level of ProGRP maintained at a relatively low level in different periods of efficacy monitoring of tumor therapy,even disease progression. Conclusions ProGRP-negative SCLC patients have a poor prognosis. It may be a special type of SCLC.

Key words: Small cell lung cancer, Gastrin releasing peptide precursor, Clinical characteristics, Neuron specific enolase

中图分类号: